Correlation Engine 2.0
Clear Search sequence regions

Although preventable by vaccination, hepatitis B infection is common, affecting more than 350 million individuals worldwide. Chronic hepatitis B infection is associated with the complications of chronic liver disease including cirrhosis and hepatocellular carcinoma. Current agents designed to target hepatitis B are hindered by the development of resistance, poor tolerability or limited efficacy and a demand for new agents and strategies continues. This review focuses on telbivudine, a novel agent in the fight against hepatitis B.


R Jones, M Nelson. Novel anti-hepatitis B agents: A focus on telbivudine. International journal of clinical practice. 2006 Oct;60(10):1295-9

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 16981973

View Full Text